Dompé Farmaceutici S.p.a
Clinical trials sponsored by Dompé Farmaceutici S.p.a, explained in plain language.
-
New drug fails to show benefit in severe COVID-19 pneumonia trial
Disease control TerminatedThis study tested whether adding reparixin to standard care could prevent death or the need for a breathing machine in 414 hospitalized adults with COVID-19 or other pneumonia. The trial was stopped early. Researchers compared reparixin to a placebo to see if it reduced severe ou…
Phase: PHASE3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental drug aims to save Insulin-Making cells in newly diagnosed type 1 diabetes
Disease control TerminatedThis Phase 2 trial tested an oral drug called ladarixin in 141 people aged 14-45 recently diagnosed with type 1 diabetes. The goal was to see if ladarixin could preserve the body's ability to produce insulin by protecting beta cells. The study was terminated early, so while it ma…
Phase: PHASE2 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Sjögren's dry eye study probes corneal nerve damage
Knowledge-focused TerminatedThis study aimed to find out how many people with Sjögren's dry eye have reduced feeling in their cornea (the clear front part of the eye). Researchers measured corneal sensitivity, tear production, and pain in 103 adults with confirmed Sjögren's syndrome and dry eye. The study w…
Sponsor: Dompé Farmaceutici S.p.A • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC